A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

About this trial

This study will compare three different doses of perineural dexmedetomidine 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg as adjuvants to local anesthetics for ultrasound-guided infraclavicular brachial plexus blocks (ICBs). Our research hypothesis is that 1.33 mcg/kg will provide a 15%-longer duration than 1mcg/kg, which in turn will provide a 15%-longer duration than 0.67 mcg/kg. Since analgesic duration and sensory duration can be influenced by intake of pain medications and surgical trauma to small cutaneous nerves, respectively, we will select motor block duration as the main outcome to better target the action of dexmedetomidine on the brachial plexus.

Eligibility criteria

Qualifiers

patients undergoing upper limb surgery at or below the elbow

age between 18 and 75 years

American Society of Anesthesiologists classification 1-3

body mass index between 18 and 35 kg/m2

Disqualifiers

adults who are unable to give their own consent

allergy or contraindication to dexmedetomidine

exposure to dexmedetomidine during the previous 48 hrs

pre-existing neuropathy (assessed by history and physical examination)

Trial design

Treatments tested in this trial

  • dexmedetomidine (perineural) 0.67 mcg/kg
  • dexmedetomidine (perineural) 1 mcg/kg
  • dexmedetomidine (perineural) 1.33 mcg/kg

Treatment groups

69 Participants
are divided into 3 treatment groups